EAACI Biologicals Guidelines—dupilumab for children and adults with moderate-to-severe atopic dermatitis

Ioana Agache; Cezmi A. Akdis; Mubeccel Akdis; Knut Brockow; Tomas Chivato; Stefano del Giacco; Thomas Eiwegger; Kilian Eyerich; Ana Giménez-Arnau; Jan Gutermuth; Emma Guttman-Yassky; Marcus Maurer; Graham Ogg; Peck Y. Ong; Liam O’Mahony; Jürgen Schwarze; Amena Warner; Thomas Werfel; Oscar Palomares; Marek Jutel; Riccardo Asero; Marta Ferrer Puga; Ignasi Figueras Nart; Massimo Gadina; Kenji Kabashima; Kazunari Sugita

doi:10.1111/all.14690

EAACI Biologicals Guidelines—dupilumab for children and adults with moderate-to-severe atopic dermatitis

Ioana Agache, Cezmi A. Akdis, Mubeccel Akdis, Knut Brockow, Tomas Chivato, Stefano del Giacco, Thomas Eiwegger, Kilian Eyerich, Ana Giménez-Arnau, Jan Gutermuth, Emma Guttman-Yassky, Marcus Maurer, Graham Ogg, Peck Y. Ong, Liam O’Mahony, Jürgen Schwarze, Amena Warner, Thomas Werfel, Oscar Palomares, Marek JutelRiccardo Asero, Marta Ferrer Puga, Ignasi Figueras Nart, Massimo Gadina, Kenji Kabashima, Kazunari Sugita

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Abstract

Atopic dermatitis imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity, co-morbidities, complexity in care pathways and differences between national or regional healthcare systems. Better understanding of the mechanisms has enabled a stratified approach to the management of atopic dermatitis, supporting the use of targeted treatments with biologicals. However, there are still many issues that require further clarification. These include the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based), its cost-effectiveness and long-term safety. The EAACI Guidelines on the use of dupilumab in atopic dermatitis follow the GRADE approach in formulating recommendations for each outcome and age group. In addition, future approaches and research priorities are discussed.

Original language	English
Pages (from-to)	988-1009
Number of pages	22
Journal	Allergy: European Journal of Allergy and Clinical Immunology
Volume	76
Issue number	4
DOIs	https://doi.org/10.1111/all.14690
State	Published - Apr 2021

Keywords

GRADE
atopic dermatitis
dupilumab
guideline

Access to Document

10.1111/all.14690

Cite this

Agache, I., Akdis, C. A., Akdis, M., Brockow, K., Chivato, T., del Giacco, S., Eiwegger, T., Eyerich, K., Giménez-Arnau, A., Gutermuth, J., Guttman-Yassky, E., Maurer, M., Ogg, G., Ong, P. Y., O’Mahony, L., Schwarze, J., Warner, A., Werfel, T., Palomares, O., ... Sugita, K. (2021). EAACI Biologicals Guidelines—dupilumab for children and adults with moderate-to-severe atopic dermatitis. Allergy: European Journal of Allergy and Clinical Immunology, 76(4), 988-1009. https://doi.org/10.1111/all.14690

@article{a87e812aa39845b0a4259a711c285ee1,

title = "EAACI Biologicals Guidelines—dupilumab for children and adults with moderate-to-severe atopic dermatitis",

abstract = "Atopic dermatitis imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity, co-morbidities, complexity in care pathways and differences between national or regional healthcare systems. Better understanding of the mechanisms has enabled a stratified approach to the management of atopic dermatitis, supporting the use of targeted treatments with biologicals. However, there are still many issues that require further clarification. These include the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based), its cost-effectiveness and long-term safety. The EAACI Guidelines on the use of dupilumab in atopic dermatitis follow the GRADE approach in formulating recommendations for each outcome and age group. In addition, future approaches and research priorities are discussed.",

keywords = "GRADE, atopic dermatitis, dupilumab, guideline",

author = "Ioana Agache and Akdis, {Cezmi A.} and Mubeccel Akdis and Knut Brockow and Tomas Chivato and {del Giacco}, Stefano and Thomas Eiwegger and Kilian Eyerich and Ana Gim{\'e}nez-Arnau and Jan Gutermuth and Emma Guttman-Yassky and Marcus Maurer and Graham Ogg and Ong, {Peck Y.} and Liam O{\textquoteright}Mahony and J{\"u}rgen Schwarze and Amena Warner and Thomas Werfel and Oscar Palomares and Marek Jutel and Riccardo Asero and Puga, {Marta Ferrer} and Nart, {Ignasi Figueras} and Massimo Gadina and Kenji Kabashima and Kazunari Sugita",

note = "Publisher Copyright: {\textcopyright} 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd",

year = "2021",

month = apr,

doi = "10.1111/all.14690",

language = "English",

volume = "76",

pages = "988--1009",

journal = "Allergy: European Journal of Allergy and Clinical Immunology",

issn = "0105-4538",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "4",

}

Agache, I, Akdis, CA, Akdis, M, Brockow, K, Chivato, T, del Giacco, S, Eiwegger, T, Eyerich, K, Giménez-Arnau, A, Gutermuth, J, Guttman-Yassky, E, Maurer, M, Ogg, G, Ong, PY, O’Mahony, L, Schwarze, J, Warner, A, Werfel, T, Palomares, O, Jutel, M, Asero, R, Puga, MF, Nart, IF, Gadina, M, Kabashima, K & Sugita, K 2021, 'EAACI Biologicals Guidelines—dupilumab for children and adults with moderate-to-severe atopic dermatitis', Allergy: European Journal of Allergy and Clinical Immunology, vol. 76, no. 4, pp. 988-1009. https://doi.org/10.1111/all.14690

TY - JOUR

T1 - EAACI Biologicals Guidelines—dupilumab for children and adults with moderate-to-severe atopic dermatitis

AU - Agache, Ioana

AU - Akdis, Cezmi A.

AU - Akdis, Mubeccel

AU - Brockow, Knut

AU - Chivato, Tomas

AU - del Giacco, Stefano

AU - Eiwegger, Thomas

AU - Eyerich, Kilian

AU - Giménez-Arnau, Ana

AU - Gutermuth, Jan

AU - Guttman-Yassky, Emma

AU - Maurer, Marcus

AU - Ogg, Graham

AU - Ong, Peck Y.

AU - O’Mahony, Liam

AU - Schwarze, Jürgen

AU - Warner, Amena

AU - Werfel, Thomas

AU - Palomares, Oscar

AU - Jutel, Marek

AU - Asero, Riccardo

AU - Puga, Marta Ferrer

AU - Nart, Ignasi Figueras

AU - Gadina, Massimo

AU - Kabashima, Kenji

AU - Sugita, Kazunari

PY - 2021/4

Y1 - 2021/4

N2 - Atopic dermatitis imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity, co-morbidities, complexity in care pathways and differences between national or regional healthcare systems. Better understanding of the mechanisms has enabled a stratified approach to the management of atopic dermatitis, supporting the use of targeted treatments with biologicals. However, there are still many issues that require further clarification. These include the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based), its cost-effectiveness and long-term safety. The EAACI Guidelines on the use of dupilumab in atopic dermatitis follow the GRADE approach in formulating recommendations for each outcome and age group. In addition, future approaches and research priorities are discussed.

AB - Atopic dermatitis imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity, co-morbidities, complexity in care pathways and differences between national or regional healthcare systems. Better understanding of the mechanisms has enabled a stratified approach to the management of atopic dermatitis, supporting the use of targeted treatments with biologicals. However, there are still many issues that require further clarification. These include the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based), its cost-effectiveness and long-term safety. The EAACI Guidelines on the use of dupilumab in atopic dermatitis follow the GRADE approach in formulating recommendations for each outcome and age group. In addition, future approaches and research priorities are discussed.

KW - GRADE

KW - atopic dermatitis

KW - dupilumab

KW - guideline

UR - http://www.scopus.com/inward/record.url?scp=85098152178&partnerID=8YFLogxK

U2 - 10.1111/all.14690

DO - 10.1111/all.14690

M3 - Article

C2 - 33538044

AN - SCOPUS:85098152178

SN - 0105-4538

VL - 76

SP - 988

EP - 1009

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

IS - 4

ER -

EAACI Biologicals Guidelines—dupilumab for children and adults with moderate-to-severe atopic dermatitis

Abstract

Keywords

Access to Document

Fingerprint

Cite this